Ancitabine

Ancitabine is the precursor of the anticancer agent Cytarabine (HY-13605), which targets targets related to cell metabolism and proliferation. Ancitabine can inhibit tumor cell proliferation, interfere with the DNA synthesis process of tumor cells, and prevent cell division. Under alkaline pH conditions, Ancitabine can be quantitatively converted into Cytarabine and can be used in the study of cancers such as colorectal cancer[1][2].

Product Specifications

CAS Number

[31698-14-3]

Product Name Alternative

Cyclocytidine; Cyclo-CMP

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

Autophagy; CMV; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Anti-infection; Autophagy; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ancitabine.html

Solubility

10 mM in DMSO

Smiles

OC[C@@H]1[C@@H](O)[C@@](O2)([H])[C@@](N(C2=N3)C=CC3=N)([H])O1

Molecular Formula

C9H11N3O4

Molecular Weight

225.20

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Aftab O, et al. Detection of cell aggregation and altered cell viability by automated label-free video microscopy: a promising alternative to endpoint viability assays in high-throughput screening. J Biomol Screen. 2015 Mar;20 (3) :372-81.|[2]Kirsch LE, et al. Aqueous conversion kinetics and mechanisms of ancitabine, a prodrug of the antileukemic agent cytarabine. J Pharm Sci. 1984 Jul;73 (7) :896-902.x